Goldman Sachs’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-155,351
| Closed | -$1.55M | – | 6498 |
|
|
2025
Q2 | $1.55M | Sell |
155,351
-432,069
| -74% | -$3.48M | ﹤0.01% | 4375 |
|
|
2025
Q1 | $3.51M | Sell |
587,420
-143,071
| -20% | -$1.05M | ﹤0.01% | 3692 |
|
|
2024
Q4 | $5.61M | Sell |
730,491
-182,522
| -20% | -$1.57M | ﹤0.01% | 3336 |
|
|
2024
Q3 | $9.32M | Buy |
913,013
+180,741
| +25% | +$2.76M | ﹤0.01% | 2802 |
|
|
2024
Q2 | $10.9M | Buy |
732,272
+16,015
| +2% | +$229K | ﹤0.01% | 2432 |
|
|
2024
Q1 | $9.77M | Sell |
716,257
-25,811
| -3% | -$281K | ﹤0.01% | 2474 |
|
|
2023
Q4 | $8.13M | Buy |
742,068
+132,856
| +22% | +$1.32M | ﹤0.01% | 2720 |
|
|
2023
Q3 | $6.67M | Sell |
609,212
-34,453
| -5% | -$441K | ﹤0.01% | 2740 |
|
|
2023
Q2 | $8.52M | Buy |
643,665
+205,556
| +47% | +$2.93M | ﹤0.01% | 2601 |
|
|
2023
Q1 | $5.96M | Buy |
438,109
+11,598
| +3% | +$208K | ﹤0.01% | 2893 |
|
|
2022
Q4 | $8.33M | Buy |
426,511
+82,910
| +24% | +$1.62M | ﹤0.01% | 2739 |
|
|
2022
Q3 | $6.55M | Sell |
343,601
-67,470
| -16% | -$1.55M | ﹤0.01% | 2895 |
|
|
2022
Q2 | $8.47M | Buy |
411,071
+227,930
| +124% | +$5.41M | ﹤0.01% | 2669 |
|
|
2022
Q1 | $5.89M | Buy |
183,141
+65,837
| +56% | +$2.39M | ﹤0.01% | 3209 |
|
|
2021
Q4 | $5.46M | Sell |
117,304
-57,980
| -33% | -$1.93M | ﹤0.01% | 3319 |
|
|
2021
Q3 | $4.73M | Buy |
175,284
+54,010
| +45% | +$1.41M | ﹤0.01% | 3415 |
|
|
2021
Q2 | $3.11M | Buy |
121,274
+54,723
| +82% | +$1.3M | ﹤0.01% | 3784 |
|
|
2021
Q1 | $2.27M | Buy |
66,551
+5,892
| +10% | +$213K | ﹤0.01% | 3864 |
|
|
2020
Q4 | $2.05M | Buy |
60,659
+34,227
| +129% | +$906K | ﹤0.01% | 3710 |
|
|
2020
Q3 | $652K | Buy |
+26,432
| New | +$711K | ﹤0.01% | 4336 |
|
Other funds holding ITOS
Goldman Sachs's ITOS Position: Q3 2025 in Review
Goldman Sachs sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 155,351 shares — an estimated $1.55M sold.
Goldman Sachs first reported a position in ITOS in Q3 2020 and held it in 20 quarters. The position peaked at $10.9M in Q2 2024. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Goldman Sachs reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Goldman Sachs sold 155,351 iTeos Therapeutics shares in Q3 2025, an estimated $1.55M.
- Goldman Sachs first reported a position in iTeos Therapeutics in Q3 2020 and held it in 20 quarters.
- Goldman Sachs's iTeos Therapeutics position peaked at $10.9M in Q2 2024.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.